{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:10:29Z","timestamp":1790691029904,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bj.2026.101037","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:54:14Z","timestamp":1789120454000},"page":"101037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural Overview of GLP-1 Analogs"],"prefix":"10.1016","author":[{"given":"Wijnand J.C.","family":"van der Velden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta F.","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9600-3254","authenticated-orcid":false,"given":"Mette M.","family":"Rosenkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2026.101037_bib1","unstructured":"RCSB PDB - human GLP-1R Uniprot ID: P43220 n.d. https:\/\/www.rcsb.org (accessed May 17, 2026)."},{"issue":"10","key":"10.1016\/j.bj.2026.101037_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-024-00649-0","article-title":"Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins","volume":"10","author":"Cong","year":"2024","journal-title":"Cell Discovery"},{"key":"10.1016\/j.bj.2026.101037_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.sbi.2018.03.008","article-title":"Peptide recognition, signaling and modulation of class B G protein-coupled receptors","volume":"51","author":"Cao","year":"2018","journal-title":"Curr Opin Struct Biol"},{"issue":"33","key":"10.1016\/j.bj.2026.101037_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/aps.2011.170","article-title":"Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors","volume":"33","author":"Pal","year":"2012","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.bj.2026.101037_bib5","doi-asserted-by":"crossref","first-page":"13188","DOI":"10.1021\/bi010902s","article-title":"Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states","volume":"40","author":"Neidigh","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.bj.2026.101037_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mrc.880","article-title":"Structure and folding of glucagon-like peptide-1-(7\u201336)-amide in aqueous trifluoroethanol studied by NMR spectroscopy","volume":"39","author":"Chang","year":"2001","journal-title":"Magnetic Resonance in Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tibs.2009.02.004","article-title":"Passing the baton in class B GPCRs: peptide hormone activation via helix induction?","volume":"34","author":"Parthier","year":"2009","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bj.2026.101037_bib8","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/j.1476-5381.2010.00834.x","article-title":"The major determinant of exendin-4\/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4","volume":"160","author":"Mann","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"1 2022","key":"10.1016\/j.bj.2026.101037_bib9","first-page":"13:92","article-title":"Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation","volume":"13","author":"Deganutti","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.bj.2026.101037_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108530","article-title":"Allosteric communication mechanism in the glucagon receptor","volume":"301","author":"van der Velden","year":"2025","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41586-023-06169-3","article-title":"Class B1 GPCR activation by an intracellular agonist","volume":"618","author":"Kobayashi","year":"2023","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.bj.2026.101037_bib12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41594-021-00674-7","article-title":"GPCR activation mechanisms across classes and macro\/microscales","volume":"28","author":"Hauser","year":"2021","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.bj.2026.101037_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tips.2014.11.001","article-title":"Generic GPCR residue numbers \u2013 aligning topology maps while minding the gaps","volume":"36","author":"Isberg","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bj.2026.101037_bib14","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.biochem.0c00626","article-title":"Activation microswitches in adenosine receptor A2a function as rheostats in the cell membrane","volume":"59","author":"Ma","year":"2020","journal-title":"Biochemistry"},{"issue":"14","key":"10.1016\/j.bj.2026.101037_bib15","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1038\/s41467-023-41893-4","article-title":"GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics","volume":"14","author":"Wright","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.bj.2026.101037_bib16","doi-asserted-by":"crossref","first-page":"15414","DOI":"10.1073\/pnas.1921851117","article-title":"A combined activation mechanism for the glucagon receptor","volume":"117","author":"Mattedi","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.bj.2026.101037_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110466","article-title":"Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors","volume":"301","author":"Liu","year":"2025","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.tips.2022.01.002","article-title":"Structural perspective of class B1 GPCR signaling","volume":"43","author":"Cong","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bj.2026.101037_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1124\/jpet.107.120006","article-title":"Oxyntomodulin differentially affects glucagon-like peptide-1 receptor \u03b2-arrestin recruitment and signaling through G\u03b1s","volume":"322","author":"Jorgensen","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bj.2026.101037_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.celrep.2018.10.018","article-title":"Insulin Secretion Depends on Intra-islet Glucagon Signaling","volume":"25","author":"Svendsen","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.bj.2026.101037_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114383","article-title":"Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system","volume":"160","author":"Gadgaard","year":"2023","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.bj.2026.101037_bib22","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/bph.15766","article-title":"Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology","volume":"179","author":"Gadgaard","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bj.2026.101037_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/er.2018-00117","article-title":"Targeting the Incretin\/Glucagon System With Triagonists to Treat Diabetes","volume":"39","author":"Capozzi","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bj.2026.101037_bib24","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bj.2026.101037_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.bj.2026.101037_bib26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bj.2026.101037_bib27","unstructured":"FDA Approves First New Molecular Entity Under National Priority Voucher Program | FDA n.d. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program (accessed July 15, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib28","unstructured":"DPP-4 \u2014 Glucagon.com n.d. https:\/\/glucagon.com\/dpp4 (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib29","article-title":"Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bj.2026.101037_bib30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0014-2999(96)00795-9","article-title":"Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor","volume":"318","author":"Knudsen","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bj.2026.101037_bib31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib32","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.bj.2026.101037_bib34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/dc12-0709","article-title":"Thefateof taspoglutide,aweeklyglp-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bj.2026.101037_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1074\/jbc.M109.033829","article-title":"Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor","volume":"285","author":"Underwood","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bj.2026.101037_bib36","doi-asserted-by":"crossref","first-page":"11340","DOI":"10.1074\/jbc.M708740200","article-title":"Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain","volume":"283","author":"Runge","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib37","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1021\/bi062309m","article-title":"Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain","volume":"46","author":"Runge","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.bj.2026.101037_bib38","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.1074\/jbc.M212147200","article-title":"The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1","volume":"278","author":"De Maturana","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bj.2026.101037_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bj.2026.101037_bib41","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1016\/S0021-9258(17)37366-0","article-title":"THE JOURNAL OF BIOLOGICAL CHEMBIXY Structure-Activity Studies of Glucagon-like Peptide-l","volume":"269","author":"Adelhorst","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib42","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bj.2026.101037_bib43","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bj.2026.101037_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.bj.2026.101037_bib45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bj.2026.101037_bib46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bj.2026.101037_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.bj.2026.101037_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bj.2026.101037_bib49","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.bj.2026.101037_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194740","article-title":"The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh","year":"2026","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bj.2026.101037_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/dom.15288","article-title":"Abolishing \u03b2-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists","volume":"26","author":"Hinds","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bj.2026.101037_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms9918","article-title":"Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bj.2026.101037_bib53","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bj.2026.101037_bib54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-pharmtox-062124-015046","article-title":"Incretin Signaling Neighborhoods and Adverse Drug Reactions","volume":"36","author":"Wright","year":"2026","journal-title":"Annual Review of Pharmacology and Toxicology Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bj.2026.101037_bib55","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.cell.2016.05.023","article-title":"The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism","volume":"165","author":"Wootten","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bj.2026.101037_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature25773","article-title":"Phase-plate cryo-EM structure of a biased agonistbound human GLP-1 receptor-Gs complex","volume":"555","author":"Liang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bj.2026.101037_bib57","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1074\/jbc.M111.309328","article-title":"Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation","volume":"287","author":"Koole","year":"2012","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib58","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1074\/jbc.RA118.003278","article-title":"Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism","volume":"293","author":"Lei","year":"2018","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.101037_bib59","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bj.2026.101037_bib60","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.0c00193","article-title":"GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats","author":"van der Velden","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bj.2026.101037_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.bj.2026.101037_bib62","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bj.2026.101037_bib63","article-title":"Cryo-EM structure of glucagon-like peptide-1 receptor (GLP-1R)-Gs complex with Exendin-phe1","author":"Zhang","year":"2025","journal-title":"Worldwide Protein Data Bank"},{"key":"10.1016\/j.bj.2026.101037_bib64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbrc.2021.09.016","article-title":"Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor","volume":"578","author":"Johnson","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bj.2026.101037_bib65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2018.01.040","article-title":"Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors","volume":"150","author":"Gabe","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bj.2026.101037_bib66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2017.02.012","article-title":"GIP(3\u201330)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release","volume":"131","author":"Sparre-Ulrich","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bj.2026.101037_bib67","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1111\/bph.16478","article-title":"Altered desensitization and internalization patterns of rodent versus human glucose-dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge","volume":"182","author":"Gasbjerg","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bj.2026.101037_bib68","unstructured":"Zepbound\u00ae (tirzepatide) Injection for Adults with Obesity or OSA n.d. https:\/\/zepbound.lilly.com\/ (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib69","unstructured":"Type 2 Diabetes Treatment to Lower A1C | Mounjaro\u00ae (tirzepatide) n.d. https:\/\/mounjaro.lilly.com\/?utm_source=GOOGLE&utm_medium=cpc&utm_campaign=21471027282&utm_content=paid_search&utm_keyword=mounjaro&gclsrc=aw.ds&gad_source=1&gad_campaignid=21471027282&gbraid=0AAAAAoh_8M__KyeDRvqs81WAwQt0vWauP&gclid=Cj0KCQjwz9_QBhD_ARIsADnSCfAD1BrlXBYBF01LRhuVnUHF49gqXcnbChNNdbhsCdtgHDrnNKZ4B7waAuP3EALw_wcB (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib70","unstructured":"The Story of Maridebart Cafraglutide (MariTide) | Amgen n.d. https:\/\/www.amgen.com\/stories\/2026\/05\/the-story-of-maridebart-cafraglutide (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib71","unstructured":"Survodutide - Pipeline - Zealand Pharma n.d. https:\/\/www.zealandpharma.com\/pipeline\/survodutide\/ (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib72","unstructured":"Product Center n.d. https:\/\/en.innoventbio.com\/ScienceAndProducts\/Pipeline\/ProductCenter (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib73","unstructured":"Lilly\u2019s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company n.d. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib74","unstructured":"News Details n.d. https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916481 (accessed May 27, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib75","unstructured":"Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes n.d. https:\/\/www.clinicaltrialsarena.com\/news\/novo-nordisk-amycretin-t2d-phase-ii-success\/ (accessed May 27, 2026)."},{"issue":"6","key":"10.1016\/j.bj.2026.101037_bib76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.bj.2026.101037_bib77","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/jcm14113812","article-title":"The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs","volume":"14","author":"Douros","year":"2025","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"10.1016\/j.bj.2026.101037_bib78","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.bj.2026.101037_bib79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib80","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bj.2026.101037_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bj.2026.101037_bib82","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2337\/db17-1385","article-title":"Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor\u2013Expressing Glutamatergic Neurons","volume":"67","author":"Adams","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib84","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bj.2026.101037_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bj.2026.101037_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101638","article-title":"Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems","volume":"66","author":"Yang","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102006","article-title":"AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys","volume":"88","author":"Jensen","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102074","article-title":"Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss","volume":"95","author":"Wean","year":"2025","journal-title":"Mol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib89","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2337\/db25-0149","article-title":"Glucose-Dependent Insulinotropic Polypeptide Is Involved in Postprandial Regulation of Splanchnic Blood Supply","volume":"74","author":"Rasmussen","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib90","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity \u2014 A Phase 2 Trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.bj.2026.101037_bib91","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s42255-025-01294-x","article-title":"GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice","volume":"7","author":"Gutgesell","year":"2025","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.bj.2026.101037_bib92","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides (NY)"},{"key":"10.1016\/j.bj.2026.101037_bib93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.bj.2026.101037_bib94","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bj.2026.101037_bib95","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dom.13494","article-title":"A novel dual glucagon\u2010like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo\u2010controlled first\u2010in\u2010human and first\u2010in\u2010patient trials","volume":"21","author":"Tillner","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bj.2026.101037_bib96","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bj.2026.101037_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib98","doi-asserted-by":"crossref","DOI":"10.2337\/db21-682-P","article-title":"682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice","volume":"70","author":"CHEN","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib99","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"issue":"16","key":"10.1016\/j.bj.2026.101037_bib100","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s13300-025-01733-8","article-title":"Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity","volume":"16","author":"Vol\u010dan\u0161ek","year":"2025","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.bj.2026.101037_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/dom.70667","article-title":"Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression","volume":"28","author":"Ahmed","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bj.2026.101037_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105862","article-title":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","volume":"118","author":"Kuhre","year":"2025","journal-title":"EBioMedicine"},{"issue":"653","key":"10.1016\/j.bj.2026.101037_bib103","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41586-026-10427-5","article-title":"GLP-1R\u2013GIPR\u2013PPAR\u03b1\/\u03b3\/\u03b4 quintuple agonism corrects obesity and diabetes in mice","volume":"653","author":"Liskiewicz","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bj.2026.101037_bib104","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00726-020-02890-9","article-title":"Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics","volume":"52","author":"Ding","year":"2020","journal-title":"Amino Acids"},{"key":"10.1016\/j.bj.2026.101037_bib105","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/ph15060740","article-title":"Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists","volume":"15","author":"Zheng","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bj.2026.101037_bib106","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/molecules30010012","article-title":"Design, Structure\u2013Activity Relationships, and Computational Modeling Studies of a Series of \u03b1-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists","volume":"30","author":"Sawyer","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bj.2026.101037_bib107","doi-asserted-by":"crossref","first-page":"11814","DOI":"10.1021\/acs.jmedchem.4c00417","article-title":"Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties","volume":"67","author":"Nielsen","year":"2024","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bj.2026.101037_bib108","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/s41557-024-01532-x","article-title":"Machine learning designs new GCGR\/GLP-1R dual agonists with enhanced biological potency","volume":"16","author":"Puszkarska","year":"2024","journal-title":"Nature Chemistry"},{"issue":"9","key":"10.1016\/j.bj.2026.101037_bib109","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"24","key":"10.1016\/j.bj.2026.101037_bib110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.bj.2026.101037_bib111","unstructured":"Find Lilly Clinical Trials | Learn About Our Research n.d. https:\/\/trials.lilly.com\/en-US (accessed June 6, 2026)."},{"issue":"43","key":"10.1016\/j.bj.2026.101037_bib112","first-page":"1741","article-title":"Are GLP-1s the first longevity drugs?","volume":"43","year":"2025","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.bj.2026.101037_bib113","first-page":"963","article-title":"Long-acting preparations of exenatide","volume":"7","author":"Cai","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bj.2026.101037_bib114","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.bj.2026.101037_bib115","doi-asserted-by":"crossref","unstructured":"Dulaglutide (Trulicity) n.d. https:\/\/doi.org\/10.2337\/dc11-s231.","DOI":"10.2337\/dc11-s231"},{"key":"10.1016\/j.bj.2026.101037_bib116","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CE.S15525","article-title":"Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes","volume":"6","author":"Barnett","year":"2011","journal-title":"Core Evid"},{"key":"10.1016\/j.bj.2026.101037_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1433587","article-title":"Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight\/obesity: results from a phase I clinical trial","volume":"15","author":"Lin","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bj.2026.101037_bib118","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.bj.2026.101037_bib119","unstructured":"Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity n.d."},{"key":"10.1016\/j.bj.2026.101037_bib120","doi-asserted-by":"crossref","DOI":"10.2337\/db26-1133-OR","article-title":"1133-OR: Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial","volume":"75","author":"GONG","year":"2026","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib121","article-title":"Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial","volume":"47","author":"Yan","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.bj.2026.101037_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101762","article-title":"Discovery of ecnoglutide \u2013 A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog","volume":"75","author":"Guo","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.bj.2026.101037_bib123","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/dom.14032","article-title":"Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes","volume":"22","author":"Yoon","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bj.2026.101037_bib124","doi-asserted-by":"crossref","DOI":"10.2337\/db19-114-LB","article-title":"114-LB: GX-G6, a Novel Long-Acting Glucagon-Like Peptide Receptor Agonist: Result of Phase I Study in Healthy Volunteers","volume":"68","author":"BYUN","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/dom.16080","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus","volume":"27","author":"Zou","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bj.2026.101037_bib126","unstructured":"Zhang C, Guo Y, Fan K, Jing S. A Phase I Study to Invesgate the Safety, Tolerability and Pharmacokinecs of a Biased GLP-1R Anbody Glutazumab P-0352 MOLECULAR DESIGN AND IN VITRO ACTIVITY Structure of Glutazumab n.d."},{"key":"10.1016\/j.bj.2026.101037_bib127","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-026-02586-8","article-title":"Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"11","author":"Ji","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bj.2026.101037_bib128","doi-asserted-by":"crossref","DOI":"10.2337\/db25-753-P","article-title":"753-P: Safety, Tolerability, PK, and Efficacy of MET097\u2014A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management","volume":"74","author":"STROH","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib129","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1464-5491.2009.02854.x","article-title":"Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes","volume":"26","author":"Kapitza","year":"2009","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.bj.2026.101037_bib130","unstructured":"Enicepatide, a cAMP Dual Signal-Biased GLP-1\/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Reduction in People With Overweight\/Obesity: a 48-Week Phase 2 Study - ICO-2026-poster-willis-enicepatide-a-camp-dual-signal-biased-glp-1gip-receptor-agonist-achieves-clinically-meaningful-weight-reduction.pdf n.d. https:\/\/medically.gene.com\/global\/en\/unrestricted\/metabolism\/ICO-2026\/ico-2026-poster-willis-enicepatide-a-camp-dual-signal-b.html (accessed July 25, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib131","unstructured":"VK2735 - Viking Therapeutics n.d. https:\/\/vikingtherapeutics.com\/pipeline\/vk2735\/ (accessed August 4, 2026)."},{"key":"10.1016\/j.bj.2026.101037_bib132","unstructured":"Zhao J, Zhao M, Song W, Wang D, Zhang X, Hui Y, et al. Efficacy and safety of HRS9531, a novel dual GLP-1\/GIP receptor agonist, in patients with type 2 diabetes mellitus (T2DM): a randomized, double-blind, placebo-controlled phase 2 trial n.d."},{"key":"10.1016\/j.bj.2026.101037_bib133","doi-asserted-by":"crossref","DOI":"10.2337\/db26-1220-OR","article-title":"1220-OR: Survodutide: Differentiated GLP-1R and Glucagon Receptor (GCGR) Pharmacology Compared with Endogenous Ligands via Time-Resolved Assays","volume":"75","author":"BERGER","year":"2026","journal-title":"Diabetes"},{"key":"10.1016\/j.bj.2026.101037_bib134","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101037_bib135","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.bj.2026.101037_bib136","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"The Lancet"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:40:13Z","timestamp":1790689213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417026000934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":136,"alternative-id":["S2319417026000934"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2026.101037","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural Overview of GLP-1 Analogs","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2026.101037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"101037"}}